Charles River Laboratories Intl. Inc (CRL) Shares Bought by Personal Capital Advisors Corp

Personal Capital Advisors Corp raised its holdings in Charles River Laboratories Intl. Inc (NYSE:CRL) by 3.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 125,306 shares of the medical research company’s stock after acquiring an additional 4,699 shares during the period. Personal Capital Advisors Corp’s holdings in Charles River Laboratories Intl. were worth $13,715,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Charles River Laboratories Intl. by 0.5% during the second quarter. Vanguard Group Inc. now owns 5,060,730 shares of the medical research company’s stock worth $511,893,000 after buying an additional 27,217 shares during the period. BlackRock Inc. boosted its position in shares of Charles River Laboratories Intl. by 4.6% during the second quarter. BlackRock Inc. now owns 4,022,882 shares of the medical research company’s stock worth $406,913,000 after buying an additional 177,239 shares during the period. FMR LLC boosted its position in shares of Charles River Laboratories Intl. by 23.8% during the second quarter. FMR LLC now owns 3,079,179 shares of the medical research company’s stock worth $311,458,000 after buying an additional 591,066 shares during the period. State Street Corp boosted its position in shares of Charles River Laboratories Intl. by 2.3% during the second quarter. State Street Corp now owns 1,268,308 shares of the medical research company’s stock worth $128,288,000 after buying an additional 28,365 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Charles River Laboratories Intl. by 14.4% during the second quarter. Renaissance Technologies LLC now owns 1,219,883 shares of the medical research company’s stock worth $123,391,000 after buying an additional 153,374 shares during the period. 96.12% of the stock is owned by hedge funds and other institutional investors.

Shares of Charles River Laboratories Intl. Inc (NYSE:CRL) opened at $107.89 on Friday. Charles River Laboratories Intl. Inc has a twelve month low of $77.61 and a twelve month high of $119.05. The stock has a market capitalization of $5,052.05, a PE ratio of 26.31, a P/E/G ratio of 1.56 and a beta of 0.88. The company has a current ratio of 1.88, a quick ratio of 1.62 and a debt-to-equity ratio of 1.13.

Charles River Laboratories Intl. (NYSE:CRL) last released its earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.08. Charles River Laboratories Intl. had a return on equity of 26.58% and a net margin of 10.72%. The business had revenue of $464.23 million for the quarter, compared to analyst estimates of $458.93 million. During the same quarter in the prior year, the company posted $1.18 earnings per share. Charles River Laboratories Intl.’s revenue was up 9.0% on a year-over-year basis. analysts expect that Charles River Laboratories Intl. Inc will post 5.14 EPS for the current fiscal year.

CRL has been the subject of several recent research reports. ValuEngine cut Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. Credit Suisse Group reaffirmed a “neutral” rating and set a $112.00 price objective (up from $95.00) on shares of Charles River Laboratories Intl. in a research report on Monday, October 16th. Zacks Investment Research cut Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Monday, November 13th. Argus initiated coverage on Charles River Laboratories Intl. in a research report on Wednesday, December 13th. They set a “buy” rating and a $120.00 price objective for the company. Finally, SunTrust Banks reaffirmed a “buy” rating and set a $113.00 price objective on shares of Charles River Laboratories Intl. in a research report on Friday, November 17th. Seven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $112.75.

In related news, insider Bradley Nixon Scharfe sold 1,000,000 shares of the company’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $0.27, for a total transaction of $270,000.00. Also, Director Online Communications Bdirect sold 131,000 shares of the company’s stock in a transaction that occurred on Thursday, January 18th. The shares were sold at an average price of $0.29, for a total value of $37,990.00. Insiders have sold 1,195,673 shares of company stock worth $2,914,046 in the last quarter. 2.20% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This article was reported by Ticker Report and is the property of of Ticker Report. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3147356/charles-river-laboratories-intl-inc-crl-shares-bought-by-personal-capital-advisors-corp.html.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.